300858 科拓生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.3815.2045.3575.4518.250
总资产报酬率 ROA (%)1.2404.8055.0655.1917.760
投入资产回报率 ROIC (%)1.3655.1375.2685.3618.085

边际利润分析
销售毛利率 (%)47.08951.50358.25254.58251.975
营业利润率 (%)16.07728.58636.15134.28734.558
息税前利润/营业总收入 (%)13.54122.98827.85826.26233.175
净利润/营业总收入 (%)14.80625.83031.16231.23929.767

收益指标分析
经营活动净收益/利润总额(%)80.89192.05683.94387.84889.411
价值变动净收益/利润总额(%)23.0363.6605.1387.2377.433
营业外收支净额/利润总额(%)0.009-0.745-0.583-0.549-1.529

偿债能力分析
流动比率 (X)4.5457.6599.92516.29615.560
速动比率 (X)4.2607.2959.44115.62714.963
资产负债率 (%)11.6448.7226.5794.2595.308
带息债务/全部投入资本 (%)-1.395-1.556-0.0800.7370.966
股东权益/带息债务 (%)-7,074.937-6,359.979-122,902.59313,323.43710,189.120
股东权益/负债合计 (%)758.8301,046.5811,419.9552,247.7411,783.798
利息保障倍数 (X)-5.337-4.267-3.446-3.350-38.431

营运能力分析
应收账款周转天数 (天)75.60561.75372.447101.453106.466
存货周转天数 (天)100.14094.396122.204119.403105.367